August 20, 2024
1 min watch
Save
VIDEO: Safety data encouraging for 4D-150 in patients with wet AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.
The study, presented at the ASRS annual meeting in Stockholm, evaluated the safety of the investigational intravitreal gene therapy from 4D Molecular Therapeutics in 32 patients with follow-up ranging from 8 to 16 weeks.
Although robust efficacy data for this compound do not exist yet, D’Amico emphasized the safety data.
“It’s encouraging that there were no alarming safety signals,” D’Amico, professor and chair of the Israel Englander department of ophthalmology at Weill Cornell Medical College, said.
Reference:
- Maturi R, et al. Phase 2 population extension cohort in the PRISM trial evaluating 4D-150 in adults with neovascular age-related macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D'Amico reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.